Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of capmatinib in advanced MET-altered non-small cell lung cancer
MOH_2017-03-14_000232Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capmatinib in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Novartis. Primary endpoint: Antitumor activity. Started Jun 2015; status: completed.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-03-14_000232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000232.